Synchron Secures $200 Million to Advance Stentrode Platform Commercialisation
US-based Synchron has raised $200 million in a Series D funding round to support the commercial rollout of its Stentrode brain-computer interface (BCI) and to develop next-generation interfaces.
Funding Round Details
The investment was led by Double Point Ventures, with participation from ARCH Ventures, Bezos Expeditions, Khosla Ventures, METIS, and NTI.
New investors joining this round include the Australian National Reconstruction Fund (NRF), Qatar Investment Authority (QIA), T.Rx Capital, K5 Global, IQT, and Protocol Labs.
Use of Funds
- Accelerate key clinical studies
- Expand team across multiple disciplines
- Drive commercial rollout of the Stentrode BCI platform
- Develop a next-generation, transcatheter high-channel whole-brain interface
CEO Statement
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis. This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.”
– Tom Oxley, Synchron Founder and CEO
Synchron aims to leverage this investment to expedite development and bring innovative brain-computer interaction technologies to market.
Stay informed and prepared with real-time data and expert insights to navigate policy changes effectively.
Summary: Synchron’s $200 million Series D funding accelerates the commercial launch of its non-surgical Stentrode BCI and supports the development of advanced brain-computer interfaces.